Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
On May 27, 2020 the U.S. Patent and Trademark Office (USPTO) proposed rule changes to govern inter partes review (IPR), post-grant review (PGR), and covered business method (CBM) review proceedings at the Patent Trial and Appeal Board (PTAB). The most significant proposal would eliminate the presumption that a genuine issue of material fact created by testimonial evidence filed with a patent owner preliminary response would be viewed in the light most favorable to petitioner when deciding to institute a review. Adoption of this rule could encourage more patent owners to file declarations with their preliminary responses, and may ultimately result in decreasing petitioner success rates in obtaining institution of review. The other changes would simply conform the rules to current USPTO practices, and are therefore less noteworthy. Below is a summary of each proposed rule change and its potential impact on PTAB practice.
*May exclude premium content
By David H. Bernstein and Jared I. Kagan
In the first case in U.S. Supreme Court history argued by telephone, the Court ruled 8-1 in favor of Booking.com, holding that it could register as a trademark its eponymous domain name BOOKING.COM.
By Jason Bloom
The Supreme Court decided two copyright cases this term, both involving states. This article discusses the cases and their likely impact on copyright law going forward.
By Rene Befurt, Marie Warchol and Anthony Nasr
As consumer surveys become increasingly common forms of evidence in matters involving copyright, patent or trademark infringement, so too do Daubert challenges that attempt to disqualify that evidence. However, getting admitted into court is no guarantee of success — you are not over the entire Daubert hurdle just yet. The next step is ensuring that your survey is convincing the fact finders that your survey’s results are dependable and useful.
By Howard Shire and Shaleen Patel
Federal Circuit: Faulty Claim Construction Does Not End Patentability Determination
Federal Circuit: Notice to Market Bio Product Not Negated By New Applications